title: Optimizing dosing of oncology drugs.
abstract: The purpose of this article is to acknowledge the challenges in optimizing the dosing of oncology drugs and to propose potential approaches to address these challenges in order to optimize effectiveness, minimize toxicity, and promote adherence in patients. These approaches could provide better opportunities to understand the sources of variability in drug exposure and clinical outcomes during the development and premarketing evaluation of investigational new drugs.
authors.affiliation: Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: L
authors.initials: L
authors.lastname: Minasian
authors.affiliation: Millennium: The Takeda Oncology Company, Cambridge, Massachusetts, USA.
authors.forename: O
authors.initials: O
authors.lastname: Rosen
authors.affiliation: Multiple Myeloma Research Foundation, Norwalk, Connecticut, USA.
authors.forename: D
authors.initials: D
authors.lastname: Auclair
authors.affiliation: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: A
authors.initials: A
authors.lastname: Rahman
authors.affiliation: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: R
authors.initials: R
authors.lastname: Pazdur
authors.affiliation: American Society of Clinical Oncology, Alexandria, Virginia, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Schilsky
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D055118:Medication Adherence; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents